Old Drugs, New Cures Act

The Old Drugs, New Cures Act creates a new "priority research drug" designation for older medications being studied for new medical uses. It directly affects drug manufacturers who want to investigate existing drugs (approved over 10 years ago) for new indications addressing significant unmet medical needs, particularly for diseases affecting 33%+ of beneficiaries in federal health programs like Medicare, Medicaid, or VA care. Key provisions require the Secretary to designate such drugs within 60 days of a request, then exclude them from Medicaid and Medicare pricing rules that typically treat minor drug modifications as "line extensions." This exclusion allows manufacturers to potentially secure better reimbursement for these repurposed drugs under current program rules. The bill changes how these specific drugs are classified in federal healthcare programs, not the drugs' medical use.